Regenicin CEO to Present at OneMedForum Business
Development and Finance Conference
LITTLE FALLS, N.J., Dec. 22, 2010 /PRNewswire-FirstCall/ -- Regenicin, Inc. (OTC Bulletin Board: RGIN) a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs, will participate in the 4th Annual OneMedForum on January 11-13, 2011 in San Francisco. Randall McCoy, CEO of Regenicin, will present the company's core concept and business model for bringing new regenerative medicine products to market.
The Forum will bring together some of the most promising emerging medtech and life science companies with strategic and financial investors focused on companies and new technologies. Focused panel sessions will also help CEOs connect with financial and strategic investors involved in specific sectors and will include networking and breakout sessions.
The conference is considered the healthcare finance community's largest gathering of the year. Information about the conference was published by onemedplace.
Regenicin, Inc. (OTC Bulletin Board: RGIN), is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin, which was founded in 2010, has assembled a world-class management team with a proven track record for developing and bringing innovative medical devices and biotechnology products to market. The company is publicly traded with headquarters in New Jersey.
Safe Harbor Statement.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Regenicin, Inc.